BrightHeart
BrightHeart SAS is a Paris-based, privately held, pre-clinical medical device company and part of Sofinnova MD Start, Sofinnova Partners' medical device accelerator. The company’s software leverages the power of artificial intelligence to analyze fetal heart ultrasound exams and support clinicians with the prenatal identification of congenital heart defects. The technology aims to improve newborn outcomes by anticipating delivery care and early intervention. BrightHeart builds on an idea by Dr. Marilyne Levy and Dr. Bertand Stos, two leading fetal cardiologists based in Paris, France.
Sector
Medical Devices
Strategies
MD Start
Status
Live
Website
www.brightheart.fr
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.